International journal of retina and vitreous · 2026
Physics-informed, phenotype-based endotamponade selection in vitreoretinal surgery: current agents and emerging vitreous substitutes.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Quiroz-Reyes Miguel A, Quiroz-Gonzalez Erick A, Quiroz Gonzalez Miguel A, Lima-Gomez Virgilio
Аннотация
BACKGROUND: Endotamponade selection is best understood as a physics-informed, phenotype-based decision rather than one driven mainly by tamponade duration or material class. This narrative review integrates density, interfacial tension, contact angle, viscosity, and drug-tamponade interactions with phenotype-specific clinical outcomes. The result is a practical framework linking tamponade behavior to retinal geography, disease complexity, and postoperative feasibility.
MAIN BODY: Lighter-than-water agents (air, expansile gases, and light silicone oils [LSOs]) preferentially support the superior retina, whereas heavy silicone oils (HSOs) and perfluorocarbon liquids (PFCLs) provide stronger inferior support. In uncomplicated rhegmatogenous retinal detachment (RRD) and many idiopathic macular holes (MHs), air or sulfur hexafluoride (SF₆) usually achieves high anatomical success with less early intraocular pressure (IOP) elevation and cataract burden than longer-acting gas or silicone oil when brief postoperative positioning is feasible. LSO remains the principal long-term option for complex, tractional, and traumatic disease because it provides durable, relatively posture-independent support, but at the cost of emulsification, cataract, pressure-related, and corneal complications. HSO and staged short-term PFCL are best viewed as selective strategies for inferior-predominant giant retinal tear (GRT) or posture-limited phenotypes, where the mechanistic rationale is strong but comparative evidence remains largely observational. Hydrogel-based vitreous substitutes are promising but remain investigational.
CONCLUSIONS: Current evidence supports a physics-informed, phenotype-based approach to endotamponade selection. Future research should prioritize phenotype-stratified comparative studies with standardized anatomical and emulsification endpoints and rigorous evaluation of emerging vitreous substitutes in well-defined clinical settings.
TRIAL REGISTRATION: Not applied.
MAIN BODY: Lighter-than-water agents (air, expansile gases, and light silicone oils [LSOs]) preferentially support the superior retina, whereas heavy silicone oils (HSOs) and perfluorocarbon liquids (PFCLs) provide stronger inferior support. In uncomplicated rhegmatogenous retinal detachment (RRD) and many idiopathic macular holes (MHs), air or sulfur hexafluoride (SF₆) usually achieves high anatomical success with less early intraocular pressure (IOP) elevation and cataract burden than longer-acting gas or silicone oil when brief postoperative positioning is feasible. LSO remains the principal long-term option for complex, tractional, and traumatic disease because it provides durable, relatively posture-independent support, but at the cost of emulsification, cataract, pressure-related, and corneal complications. HSO and staged short-term PFCL are best viewed as selective strategies for inferior-predominant giant retinal tear (GRT) or posture-limited phenotypes, where the mechanistic rationale is strong but comparative evidence remains largely observational. Hydrogel-based vitreous substitutes are promising but remain investigational.
CONCLUSIONS: Current evidence supports a physics-informed, phenotype-based approach to endotamponade selection. Future research should prioritize phenotype-stratified comparative studies with standardized anatomical and emulsification endpoints and rigorous evaluation of emerging vitreous substitutes in well-defined clinical settings.
TRIAL REGISTRATION: Not applied.